Jul 29, 2020 • 8:05 am EDT Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Jul 8, 2020 • 8:05 am EDT Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
Jun 29, 2020 • 8:05 am EDT Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Jun 22, 2020 • 8:05 am EDT Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Jun 1, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
May 27, 2020 • 8:05 am EDT Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 22, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
May 11, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates